Lyra Therapeutics Inc. (LYRA): Price and Financial Metrics


Lyra Therapeutics Inc. (LYRA): $9.19

0.19 (+2.11%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

LYRA Stock Price Chart Interactive Chart >

Price chart for LYRA

LYRA Price/Volume Stats

Current price $9.19 52-week high $16.50
Prev. close $9.00 52-week low $6.85
Day low $8.89 Volume 326,800
Day high $9.38 Avg. volume 137,196
50-day MA $9.23 Dividend yield N/A
200-day MA $11.23 Market Cap 119.48M

Lyra Therapeutics Inc. (LYRA) Company Bio


Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer and is headquartered in Watertown, MA.


LYRA Latest News Stream


Event/Time News Detail
Loading, please wait...

LYRA Latest Social Stream


Loading social stream, please wait...

View Full LYRA Social Stream

Latest LYRA News From Around the Web

Below are the latest news stories about Lyra Therapeutics Inc that investors may wish to consider to help them evaluate LYRA as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

Good morning, investors!

William White on InvestorPlace | June 9, 2021

Lyra Therapeutics Stock Is Trading Higher After Positive FDA Meeting Outcome For Rhinosinusitis Program

Lyra Therapeutics Inc (NASDAQ: LYRA) announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the FDA for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS). Lyra and the FDA established key elements of the Phase 3 program. The single primary endpoint will evaluate improvement at week 24 using a composite score of three cardinal symptoms of CRS: nasal blockage, nasal discharge, and facial pain. Based on the Agency's suggestion, Lyra will enroll approxi

Yahoo | June 9, 2021

Lyra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for LYR-210 for the Treatment of Chronic Rhinosinusitis

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to the ear, nose and throat (ENT) passages and other diseased tissues, today announced the successful outcome of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for LYR-210, its lead candidate for the treatment of chronic rhinosinusitis (CRS).

Yahoo | June 8, 2021

Lyra Therapeutics and LianBio Announce Strategic Partnership and Exclusive License Agreement to Develop and Commercialize LYR-210 in Greater China and Other Asian Markets

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and local delivery of medications to ear, nose and throat (ENT) passages and other diseased tissues, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced a strategic partnership and exclusive license agreement for the development and commercializa

Yahoo | June 2, 2021

Lyra Therapeutics to Present at the William Blair 41st Annual Growth Stock Conference

Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat (ENT) diseases, today announced that Maria Palasis, Ph.D., Lyra’s President and Chief Executive Officer, will participate in a fireside chat at the William Blair 41st Annual Growth Stock Conference on Thursday, June 3, 2021 at 11:30am EDT.

Yahoo | June 1, 2021

Read More 'LYRA' Stories Here

LYRA Price Returns

1-mo 21.08%
3-mo -33.88%
6-mo -4.37%
1-year -34.36%
3-year N/A
5-year N/A
YTD -19.39%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8018 seconds.